Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ceritinib
Find trials that include:  Any drugs shown
Results 1-10 of 10 for your search:
Start Over
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CLDK378A2303, NCI-2014-00520, 2012-005637-36, NCT01828112
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CLDK378AUS23, NCI-2014-02128, NCT02186821
A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLDK378A2205, NCI-2015-00957, NCT02336451
Ceritinib in Treating Patients with Relapsed or Refractory ALK-Positive Hematologic Malignancies
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: Pro00056623, NCI-2015-00732, NCT02343679
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 17
Trial IDs: CLDK378X2103, NCI-2013-00903, 2012-002074-31, NCT01742286
Ceritinib and Combination Chemotherapy in Treating Patients with Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 248813, NCI-2014-01766, NCT02227940
Ceritinib and Everolimus in Treating Patients with Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0890, NCI-2015-00062, NCT02321501
Ceritinib in Treating Patients with Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 082014-029, NCI-2014-02360, NCT02289144
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: CLDK378A2402, NCI-2013-01953, NCT01947608
Start Over